Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle 
12/18/15MedGenome Now Offering Panorama™ NIPT in India via Natera's Constellation™ Cloud-based Software Platform
SAN CARLOS, Calif., Dec. 18, 2015 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that MedGenome, a leader in clinical genomic testing and a provider of genomic solutions for personalized healthcare in India, is now performing the Panorama non-invasive prenatal test (NIPT) at its genetics laboratory in Bangalore, leveraging Natera's proprietary technology and Constellation, Natera's cloud-based ... 
12/04/15Natera Announces the Appointment of Michael C. Little as Senior Vice President, R&D
SAN CARLOS, Calif., Dec. 4, 2015 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that Michael C. Little, Ph.D. has joined the company as Senior Vice President, Research and Development. Prior to Natera, Dr. Little was the Global Head of Diagnostics Development at Novartis. During his tenure, Dr. Little managed the diagnostic development of all molecular diagnostic programs, as well as oncology a... 
11/24/15Natera to Present at the 27th Annual Piper Jaffray Health Conference
SAN CARLOS, Calif., Nov. 24, 2015 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will present at the 27th Annual Piper Jaffray Health Conference in New York on Wednesday, December 2, 2015 at 1:00 p.m. ET.  Matthew Rabinowitz, Ph.D., CEO of Natera, will discuss the Company's financial results, business activities and financial outlook. Natera will offer a live audio webcast of the pr... 
11/19/15Natera Announces the Appointment of Jimmy Lin as Chief Scientific Officer for Oncology
SAN CARLOS, Calif., Nov. 19, 2015 /PRNewswire/ -- Natera, Inc., (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that Jimmy Lin, MD, PhD, MHS has been appointed as Chief Scientific Officer for Oncology. Dr. Jimmy Cheng-Ho Lin joins Natera coming from a long history as a pioneer in cancer genomics. Most recently, he led the clinical genomics program at the National Cancer Institute at the National Institutes of Health. Previously, at ... 
11/12/15Natera Reports Third Quarter 2015 Financial Results
SAN CARLOS, Calif., Nov. 12,  2015 /PRNewswire/ -- Natera,  Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis  of circulating cell-free DNA, today reported financial results for the third quarter ended September 30, 2015 and provided an update on recent business progress. Recent Accomplishments & Highlights Accessioned greater than 83,000 tests in the third quarter of 2015 compared to approximately 57,000 tests accessioned in the third quarter of 2014, a... 
11/03/15LifeLabs Now Offering Panorama™ NIPT in Canada via Natera's Constellation Software Platform
Constellation™ software provides access to Natera's innovative bioinformatics through the cloud SAN CARLOS, Calif., Nov. 3, 2015 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that LifeLabs Medical Laboratory Services ("LifeLabs"), a leading Canadian laboratory services provider, is now performing the Panorama non-invasive prenatal test (NIPT) at its genetics laboratory in Toronto, lever... 
10/30/15Natera to Release Third Quarter 2015 Results on November 12, 2015
SAN CARLOS, Calif., Oct. 30, 2015 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its third quarter ended September 30, 2015 after the market close on November 12, 2015. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook. Event:    Natera's... 
10/28/15Natera Study Demonstrates Performance of mmPCR Technology in Identifying Breast Cancer
mmPCR can accurately detect CNVs with approximately 5 times higher sensitivity than existing methods First published report demonstrating detection of subclonal mutations in plasma that may be missed in tumor tissue biopsies SAN CARLOS, Calif., Oct. 28, 2015 /PRNewswire/ -- Natera, Inc., (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced a study published in the October 2015 issue of Translational Oncology showing that Natera's... 
10/16/15Natera to Present at ASRM Annual Meeting
SAN CARLOS, Calif., Oct. 16, 2015 /PRNewswire/ -- Natera, Inc., (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that clinical research associated with its suite of reproductive genetic tests and screens will be highlighted during three scientific sessions at the American Society of Reproductive Medicine (ASRM) annual meeting, to be held October 17 – 21 in Baltimore, MD.  Natera Presentations at ASRM Size Matters: SNP-based ... 
10/06/15Natera to Present at ASHG Annual Scientific Conference
SAN CARLOS, Calif., Oct. 6, 2015 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that clinical research associated with its suite of genetic testing products will be highlighted during three scientific sessions at the American Society of Human Genetics (ASHG) annual meeting, to be held October 6–10 in Baltimore. MD. Natera Presentations at ASHG Detection of SNVs and CNVs in Circulating... 
08/12/15Natera Reports Second Quarter 2015 Financial Results
SAN CARLOS, Calif., Aug. 12, 2015 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the second quarter ended June 30, 2015 and provided an update on recent business progress. Recent Accomplishments & Highlights Achieved Total Revenue of $45.1 million in the second quarter of 2015, an increase of 26% over the same period of the prior year. Accessioned roughly 69,00... 
08/10/15Recent Publication Supports the Cost Effectiveness of NIPT for All Pregnant Women, Regardless of Prior Risk
SAN CARLOS, Calif., Aug. 10, 2015 /PRNewswire/ -- Natera, Inc., (Nasdaq: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced new data that supports the use of non-invasive prenatal testing (NIPT) as a first line screening for chromosomal aneuploidies and related conditions. Peter Benn, DSc., Professor of Genetics at the UCONN Health Center, initiated a comprehensive economic analysis of NIPT and alternative methods, one of the first... 
08/04/15Natera to Release Second Quarter 2015 Results on August 12, 2015
SAN CARLOS, Calif., Aug. 4, 2015 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its second quarter ended June 30, 2015 after the market close on August 12, 2015. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook. Event:    Natera's Second ... 
07/08/15Natera Selected for NHS-Funded TRACERx Study of Lung Cancer Heterogeneity Using Cell-Free Tumor DNA
-- Natera's proprietary mmPCR technology to provide high sensitivity for blood-based detection of elusive subclonal tumor variations -- SAN CARLOS, Calif., July 8, 2015 /PRNewswire/ -- Natera, Inc., a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced a research collaboration with University College London (UCL) Cancer Institute, where the Institute will use Natera's proprietary technology to detect variations in cell-free circulating tumor D... 
07/01/15Natera Announces Pricing of Initial Public Offering
SAN CARLOS, Calif., July 1, 2015 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA) today announced the pricing of its upsized initial public offering of 10,000,000 shares of its common stock at a price to the public of $18.00 per share before underwriting discounts, commissions and estimated expenses. In addition, Natera has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock to cover over-allotments, if any. The shares are expected to begin t... 
05/28/15First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test
Precancerous condition identified in first trimester with PanoramaTM prenatal screen SAN CARLOS, Calif., May 28, 2015 /PRNewswire/ -- Natera, Inc., a leader in non-invasive genetic testing, today announced a study published in Ultrasound in Obstetrics & Gynecology demonstrating that the Panorama single-nucleotide polymorphism (SNP)-based non-invasive prenatal test (NIPT) can identify a complete molar pregnancy in the first trimester. A study based upon data collected in the UK... 
04/24/15Natera and LifeLabs Announce Agreement for Panorama™ Non-Invasive Prenatal Test (NIPT) in Canada
SAN CARLOS, Calif., April 24, 2015 /PRNewswire/ -- Natera, Inc., a global leader in non-invasive genetic testing, and LifeLabs Medical Laboratory Services ("LifeLabs") today announced a new agreement that gives LifeLabs the rights to perform non-invasive prenatal testing (NIPT) in Canada using Natera technology. Pregnant women and their healthcare professionals will receive faster information about their fetus using world-class technology delivered through a Canadian based laboratory. Today... 
04/15/15Study Published in the Journal Science Identifies the First Genetic Variant Directly Correlated to Mitotic-Origin Aneuploidy in Human Embryos
- Study analyzed over 20,000 unique embryos using Spectrum™ Preimplantation Genetic Screening from Natera - SAN CARLOS, Calif., April 15, 2015 /PRNewswire/ -- Natera, Inc., a leader in non-invasive genetic testing, announced the publication of a study in the current issue of Science, which describes the identification of a genetic variant that influences the likelihood of aneuploidy in preimplantation embryos. Variants of this gene may help explain why some women take long... 
04/06/15Natera, Inc., Non-Invasive Genetic Testing Leader, Secures $55 Million in Private Financing
SAN CARLOS, Calif., April 6, 2015 /PRNewswire/ -- Natera, Inc., a leader in non-invasive genetic testing, today announced that it has raised approximately $55.5 million in funding led by Silicon Valley life sciences investment firm Sofinnova Ventures. This financing round also includes participation from Capital Research and Management, Franklin Templeton Investments, Jennison Associates, RA Capital Management, Healthcor Partners and OrbiMed Advisors."We are very pleased to have led Natera's lat... 
Shareholder Tools